Mode
Text Size
Log in / Sign up
Phase 3 Completed N=66 Treatment

A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension

Source: ClinicalTrials.gov NCT00457626 ↗
Enrolled (actual)
66
Serious AEs
6.1%
Results posted
May 2021
Primary outcomePrimary: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) — 114.7; -11.2 millimeters of mercury (mmHg)
◆ Published Evidence
Established
22citations · ~2 / year
Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age.
Journal of hypertension · 2013 · High-confidence link

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of long-term use (up to 18 weeks) of valsartan in children 6 months to 5 years old with hypertension.

Linked Publications

  • Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age.
    Journal of hypertension · 2013 · 22 citations · High-confidence link

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)
114.7; -11.2
PRIMARY
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)
70.7; -6.6
PRIMARY
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
38; 4

Eligibility Criteria

Inclusion criteria

  • Participants who qualified and entered the core study.
  • Participants who participated in the core study, completed Period 1 and were re-randomized in Period 2 and continued for at least 3 days in Period 2.

Exclusion criteria

  • Participants who did not complete Period 1 of the core study.
  • Participants who were re-randomized in Period 2 of core study but did not continue for => 3 days in Period 2 of the core study.
  • Participants who experienced any adverse events considered serious or drug related in the core study.
  • Participants excluded from the core study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00457626) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search